Iloprost inhalation for the treatment of severe persistent pulmonary hypertension of the newborn, experience at QSNICH.
BACKGROUND
Persistent pulmonary hypertension of the newborn (PPHN) is the most serious condition that causes high mortality in term and post term infants. The authors have an experience of using high frequency oscillatory ventilation (HFOV) and inhaled nitric oxide (iNO) for treatment of this condition with a good result. However, due to high cost of iNo, other pulmonary vasodilators have been use. Sildenafil had some side effects of systemic hypotension. Thus, inhaled iloprost was introduced for treatment of PPHN at our institute.


OBJECTIVE
To evaluate the outcome of inhaled iloprost for the treatment of PPHN.


METHODS
This was a retrospective study. The data from medical records of newborns, diagnosed as persistent pulmonary hypertension of the newborn and had received inhaled iloprost from October 1st, 2008-October 31st, 2012, were reviewed.


RESULTS
Nineteen cases of PPHN treated with inhaled iloprost were reviewed. Male to female ratio was 1.3 7:1 (11:8). Mean birth weight and gestational age of these patients were 2,997 ± 531.63 grams and 37.9 ± 2.51 weeks, respectively. Meconium aspiration syndrome was the leading underlying cause of this condition. The mortality rate in this study was 21% (4 from 19 cases). After the addition of inhaled iloprost, the oxygen index (OI) in the survivor group decreased significantly at one hour after treatment (from 32.89 to 22.06, 18.76, 13. 76 at 1, 6, 12 hours, respectively). Oxygen saturation (SpO2) continued increasing after treatment in the survivor group (from 82.40% to 92.20%, 95.00%, 95.80% at 1, 6, 12 hours, respectively) with significant difference at one hour. There was a significant difference of OI and SpO2 between the survivor and non-survivor groups after treatment. Low Apgar score at 5 minutes and early diagnosis of PPHN were found statistically significant different in the non-survivor compared to the survivor groups.


CONCLUSIONS
Inhaled iloprost could be used as an alternative treatment of PPHN without side effects of systemic hypotension.
Uraiwan
U
Chotigeat
Maneewan
M
Champrasert
Meera
M
Khorana
Varaporn
V
Sangtaweesin
Wiboon
W
Kanjanapattanakul
D000280:Administration, Inhalation; D004334:Drug Administration Schedule; D005260:Female; D006612:High-Frequency Ventilation; D006801:Humans; D016285:Iloprost / Q000008:administration & dosage*; D007231:Infant, Newborn; D008168:Lung / Q000187:drug effects; D008297:Male; D009569:Nitric Oxide / Q000008:administration & dosage; D010100:Oxygen / Q000008:administration & dosage; D010547:Persistent Fetal Circulation Syndrome / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage; D011687:Purines / Q000008:administration & dosage; D012189:Retrospective Studies; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000008:administration & dosage; D013785:Thailand; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage
D010879:Piperazines; D011687:Purines; D013449:Sulfonamides; D014665:Vasodilator Agents; D009569:Nitric Oxide; D000068677:Sildenafil Citrate; D016285:Iloprost; D010100:Oxygen